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Dopaminergic effects on in vitro osteogenesis
Dong Joon Lee1, Henry C Tseng2, Sing Wai Wong3, Zhengyan Wang4, Meng Deng3 and Ching-Chang Ko1,3,5
Multiple growth factors (e.g., BMP2, TGF-b1, FGF2) and isolated genes have been shown to improve
osteoblastic proliferation and mineralization, advancing bone tissue engineering. Among these factors, both
polydopamine (PDA) and dopamine (DA) monomer have recently been reported to increase osteoblast
proliferation and mineralization in vitro. Although a well-characterized neurotransmitter, DA’s role in the
bone is unknown. We hypothesize that DA can directly act on osteoblasts, and examined whether osteoblasts
express DA receptors that respond to exogenous DA. mRNAs and protein cell lysates were obtained from
MC3T3-E1 cells during osteogenic differentiation phase. Reverse transcription polymerase chain reaction
and western blot analysis were used to examine the expression of DA receptors, D1–D5. Dose-response effect
and time course of DA treatment on cell proliferation, mineralization, and osteogenic differentiation were
investigated at pre-determined days. Real-time PCR was performed to investigate whether DA affects
osteogenic gene expression (ALP, BSP, OC, OSX, RUNX2, and Collagen1a2) with or without receptor
antagonists (SCH233390 and GR103691). Two-way ANOVA was used for statistical analysis. All five DA
receptors (D1, D2, D3, D4, and D5) mRNAs and proteins were expressed in MC3T3-E1 cells. DA treatment
increased cell proliferation for up to 7 days (P , 0.05). Osteogenic mineralization was significantly greater in
the DA-treated group than control group (P , 0.05). Finally, expression of all the osteogenic genes was inhibited
by DA receptor antagonists for D1, D3, and D5. Our findings suggest that MC3T3-E1 osteoblasts express
functional DA receptors that enhance proliferation and mineralization. PDA is not biologically inert and has
important implications in orthopedic applications. Furthermore, osteoblast differentiation might be regulated
by the nervous system, presumably during bone development, remodeling, or repair.
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INTRODUCTION
Three-dimensional (3D) scaffolds for tissue regeneration
require mechanical strength and the desired environment
for seeded cells to gain functionality in the scaffold mate-
rials. Scaffolds that release soluble bioactive factors
achieved higher success rates of tissue regeneration
compared to direct delivery of signal molecules into the
regeneration site or on a porous scaffold.1 Oxidative
polymerization of dopamine (DA) was recently used in
our laboratory to increase the mechanical property of
3D bone scaffolds made of Hydroxyapatite-Gelatin
Calcium Silicate (HGCS) by providing an interpenetrating
polydopamine (PDA) network (HGCS-PDA).2
Surface modification with PDA, inspired by marine
bivalve mollusks and mussels, has been used to promote
cell adhesion in wet environments and on surfaces resist-
ant to cell adhesion.3 Under alkaline condition, the
hydroxyl or C5O groups in 1,2-dihydroxybenzene oxidize
to Quinone and induce polymerization of the DA. This
reaction has been applied to form a thin layer coating
the substrates by covalent bond, hydrogen bond, and
metal chelation.4
The adhesion of mouse pre-osteoblasts MC3T3-E1 cells
were significantly improved on the surface of PDA modi-
fied materials such as polyethylene, polytetrafluoroethy-
lene, silicone, and polydimethylsiloxane.5–7 Additionally,
1NC Oral Health Institute, School of Dentistry, University of North Carolina, CB #7454, Chapel Hill, NC 27599, USA; 2Duke Eye Center and Department
of Ophthalmology Duke University Medical Center, Durham, NC 27710, USA; 3Oral Biology Program, School of Dentistry, University of North
Carolina, CB #7454, Chapel Hill, NC 27599, USA; 4Department of Pediatric Dentistry, School of Dentistry, University of North Carolina, CB #7454,
Chapel Hill, NC 27599, USA and 5Department of Orthodontics, School of Dentistry, University of North Carolina, CB #7454, Chapel Hill, NC 27599,
USA
Correspondence: Ching-Chang Ko (Ching-Chang_Ko@unc.edu)
Received: 11 January 2015; Revised: 21 April 2015; Accepted: 14 May 2015
OPEN Citation: Bone Research (2015) 3, 15020; doi:10.1038/boneres.2015.20
 2015 Sichuan University All rights reserved 2095-4700/15
www.nature.com/boneres
PDA coating on substrates such as titanium and electro-
spun polymers has been shown to promote osteogenic
differentiation.8–9 While these exciting results have im-
proved cell adhesion, they are restricted to two-
dimensional surface coating.
We were the first to report the amalgamation of PDA in a
3D composite structure instead of a surface coating.
The use of PDA in our HGCS-PDA substrate increased the
mechanical strength by 30% compared to scaffolds with
no DA. Surprisingly, the HGCS-PDA scaffold was found to
release DA into the surrounding liquid environment, which
was detected by using high-performance liquid chromato-
graphy (HPLC).2 In general, DA is known to function as a
neurotransmitter in neurons by binding to D1 and D2 types
of DA receptors. While signals from D1-type receptors
transduce through G proteins to activate adenylyl cyclase,
forming cyclic adenosine monophosphate (cAMP) and
activating protein kinase A (PKA), D2-type receptors block
this signaling by inhibiting adenylyl cyclase.10
Recent data suggest that osteoblasts might respond to
neurotransmitters. For instance, sensory and sympathetic
nerve fibers directly transduce chemical messenger to the
bone and periosteum.11 Also, the finding of nerve endings
directly contacted with bone cells may have possible
effect on the bone remodeling. Axons containing cate-
cholamine were found near osteoblasts in vivo.12 The pres-
ence of beta adrenergic receptors in both osteoblasts
and osteoclasts further support the existence of receptors
for neurotransmitters and neuropeptide from sensory and
sympathetic nerve fibers.13 Finally, many studies showed
that damaged or missing sympathetic nerves result in
abnormal bone formation and bone mass.14 Therefore,
these findings implicate that osteoblasts may respond to
neurotransmitters such as DA.
In addition to the DA effects on osteoblasts, there were
relevant evidences of DA receptor and DA active trans-
porter (DAT) can also influence osteogenic activity.
Hanami et al. have demonstrated that D2-like DA recep-
tor signaling suppressed human osteoclastogenesis.15
Furthermore, Bliziotes et al. have shown mice deleted for
DAT gene exhibit reduced bone mass.16 These findings
indicate that dopaminergic signaling plays an important
role in bone homeostasis via direct effects upon osteo-
clast differentiation and the deletion of the DAT gene
results in deficiencies in skeletal structure and integrity.
To determine whether DA can influence osteoblast pro-
liferation and differentiation, we hypothesize osteoblasts
may express DA receptors and respond to the DA. To test
the hypothesis, MC3T3-E1 osteoblast cells were examined
for DA receptor expression using RT-PCR and western blot
analysis. Potential effects of the DA on osteogenic gene




MC3T3-E1 pre-osteoblasts were obtained from ATCC
(Subclone 14, CRL-2594).17 The cells were cultured and
expanded in growth media (alpha minimal essential med-
ium (a-MEM) containing 10% fetal bovine serum (FBS) and
1% penicillin and streptomycin) and were differentiated
with growth media supplemented with 10 mmolNL21 beta
glycerophosphate and 0.2 mmol?L21 ascorbic acid at
376C under 5% CO2. The media was changed every 3 days.
RT-PCR for DA receptor expression
Total RNA was isolated from 5 3 106 cells by following
the instructions from QiagenRNeasy Mini kits (Qiagen,
Valencia, CA, USA), and then the RNA was reverse-
transcribed into cDNA using an QuantiTect Reverse
Transcription Kit (Qiagen, Valencia, CA, USA). Oligo-
nucleotide primers for the PCR were designed for mouse
DA receptors as described in Table 1. For the first step of
the PCR, the conditions for the DA receptors and GAPDH
were 29 cycles of denaturation (at 946C for 40 seconds),
annealing (at 556C for 45 seconds), and extension (at 726C
for 40 seconds), followed by a final 5-minute extension at
726C. RNAs extracted from fresh mouse brain were used as
a control to identify the correct size of DA mRNAs from
MC3T3-E1 cells. To reduce non-specific binding in PCR pro-
ducts, nested PCR was performed. A 1 mL of amplified PCR
products (D1–D5 and GAPDH) from the first step was used
as a template to initiate another PCR reaction, which
was performed under the same conditions as first step
except that different primers were used for the nested
PCR (Table 1). The PCR products from both first and second
steps were separated by electrophoresis through a 1%
agarose gel containing GelRed Nucleic Acid Stain
(Biotium, Inc., Hayward, CA, USA), and the image was cap-
tured by ImageQuant LAS 4000 (GE, Piscataway, NJ, USA).
Western blot analysis for DA receptors
MC3T3-E1 cells under osteogenic differentiation for 0, 4, 7,
and 14 days were lysed with RIPA lysis buffer (50 mmol?L21
Tris-HCl: pH 8.0, 5 mmol?L21 EDTA, 150 mmol?L21 NaCl, 1%
Triton X-100, 1 mmol?L21 phenylmethylsulfonyl fluoride, and
phosphatase & protease inhibitor cocktail) for 10 minutes.
After centrifugation at 14 000 rpm?min21, supernatant
was collected as a whole-cell lysate.
Mouse brain tissue was used as positive control. All ani-
mal works were performed with Institutional Animal Care
and Use Committee (IACUC) approval at Duke University.
Total protein was measured by using Pierce BCA Protein
Assay Kit (Thermo Fisher Scientific Inc., Rockford, IL, USA).
Cell lysate from each group containing 15 mg of protein
was loaded to and separated through 12% NuPAGE
SDS-PAGE Gel (Invitrogen, Carlsbad, CA, USA), and then
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transferred onto a nitrocellulose membrane (Millipore,
Billerica, MA, USA) by using Trans-Blot SD Semi-Dry Transfer
Cell (Bio-Rad, Hercules, CA, USA). After blocking for 30 min-
utes, the membrane was incubated overnight at 46C with
the anti-DA receptors 1 (Abcam, Cambridge, MA, USA),
2 (Alomone Labs, Jerusalem, Israel), 3 (Alomone Labs,
Jerusalem, Israel), 4 and 5 (Abcamh, Cambridge, MA,
USA) antibodies (1:500 ratio). After subsequent washing,
the membrane was incubated for 1 hour with secondary
antibodies conjugated to HRP (Milipore, Billerica, MA,
USA), rewashed, and developed using an enhanced
chemiluminescence solution (Thermo Fisher Scientific
Inc., Rockford, IL, USA). The band images were captured
by ImageQuant LAS 4000 (GE, Piscataway, NJ, USA). Beta
actin (Abcamh, Cambridge, MA, USA) was used as a
loading control and for normalization.
Optimization of DA concentration
MC3T3-E1 cells (2 3 105 per 35 mm dish) were maintained
in the growth media for 24 hour. DA was dissolved in
molecular grade ultrapure water (Mediatech, Inc.,
Manassas, VA, USA) and filter through 0.2 mmol?L21 pore
syringe filters. The cells were then exposed to DA in different
final concentrations (0, 50, 100, and 200 mmol?L21) for 24,
36, 48, and 72 hours, respectively.
The dose and time effect of DA on MC3T3-E1 cells were
determined with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt
(MTS) assay according to the manufacturer’s instructions
(CellTiter96; Promega, Madison, WI, USA). Briefly, 40 mL of
MTS reagent in 500 mL of basal media was added to the
cells in each dish at the end of the designed cultivation
period and incubated for 1 hour at 376C. Aliquots of 100 mL
were removed for analysis. Colored formazan products
were quantified by measuring absorbance at 490 nm
using a microplate reader (Bio-Rad Model 550, Life
Science Research, Hercules, CA, USA). Three samples
were tested with triplicate at each time point for each
group.
Proliferation assay
MC3T3-E1 cells (5 3 104 cells per 35 mm dish) were seeded
and attached overnight, and then stimulated with DA. The
cells were supplied with fresh culture media containing
50 mmol?L21 of DA every 48 hours during the culture period.
Cell proliferation also was carried out under low FBS (3%)
containing growth media. After 1, 3, 5, and 7 days in cul-
ture, the absorbance of MTS solution from each well was
measured at 490 nm using a microplate reader. For those
proliferating cells, 5-bromo-29-deoxyuridine (BrdU: Life
Technologies, Grand Island, NY, USA) was incorporated
with cells for 2 hours and detected using anti-BrdU anti-
body as instructed by company protocol.
Mineralization assay with cetylpyridiniumchloride
quantitation
MC3T3-E1 cells were seeded (2 3 105 cells per 35 mm dish)
and supplied with fresh osteogenic media every 3 days.
A total of four groups were examined for mineral forma-
tion: the cells cultured with osteogenic media, osteogenic
media containing 50 mmol?L21 DA, growth media contain-
ing 50 mmol?L21 DA, and growth media only. A control
group without cells was also examined. After 7, 14, 18,
and 21 days the cells were fixed with 75% cold ethanol for
30 minutes and then stained with 1% Alizarin Red (Acros
Organics, Geel, Belgium) solution (pH 4.2) for 10 minutes
at RT. The cells were rinsed with dH2O six times and air dried.
Color images of the mineral deposition were acquired using
an Olympus DP12 camera (Olympus Optical Co. Ltd,
Japan) attached to a Nikon Eclipse Ti-U microscope
(Nikon Instruments, Melville, NY, USA). To quantify Alizarin
Red S-retained minerals, 10% (v/w) cetylpyridinium chloride
(CPC; Sigma-Aldrich, St. Louis, MO, USA) in sodium phos-
phate was used and measured at 570 nm.
Real-time PCR for osteogenic gene expression with DA
receptor blockers
MC3T3-E1 cells were culture with both growth and osteo-
genic media for 0, 4, and 7 days. DA receptor antagonists
Table 1. Primers for RT-PCR and nested PCR of dopamine receptors18
Target RT-PCR Primer Sequence (59–39) Size (bp) Nested PCR Primer Sequence (59–39) Size (bp)
DrD1a F: ACCTACATGGCCCITGGATGGC 363 F: CCCGTAGCCAITATGATCGT 151
R: GGGAGCCAGCAGCACACGAA R: AITGAGAGCAITCGACAGGG
DrD2 F: AGCCGCAGGAAGCTCTCCCA 284 F: TGGCTGCCCTTCTTCATCACGC 157
R: AGCTGCTGTGCAGGCAAGGG R: TGAAGGCCTTGCGGAACTCAATGT
DrD3 F: CCTGTCTGCGGCTGCATCCC 252 F: ATGGAGCACATAGAAGACAAACC 148
R: TCTCCACTTGGCTCATCCC R: AGTTTGGATGCCTCAAGGC
DrD4 F: TCCTGCCGGTGGTAGTCGGG 276 F: GTGTGTTGGACGCCITTCTT 218
R: GCCAGCGCACTCTGCACACA R: CTCCTTGACCTCTGCAGGAC
DrD5 F: TGGGAGGAGGGGCAGTCACC 642 F: GCTTTGCCAGTTGGTGCTCAGTG 134
R: AGGTGGGCTCCTCCGTGAGC R: GGCCCTTTGTTCTGCGAGITCCC
GAPOH F: GCCACCCAGAAGACTGTGGAT 477 F: GCCACCCAGAAGACTGTGGAT 477
R: TGGTCCAGGGITTCTTACTCC R: TGGTCCAGGGTHCITACTCC
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SCH233390 (Tocris Bioscience, Bristol, UK) for D1 and D5
and GR103691 (Tocris Bioscience, Bristol, UK) for D3 was
treated in each 35 mm dish with final concentration of
1 mmol?L21 and 0.5 mmol?L21, respectively. After 30 min-
utes of antagonists treatment, DA solution was added
directly to the experimental group for a final concentra-
tion of 50 mmol?L21. cDNA was synthesized as previously
described in RT-PCR. Real-time PCR was performed using
the 7200 Fast Real-Time PCR System (Applied Biosystems,
Bedford, MA, USA) to determine mRNA expression of each
osteogenic specific genes (Table 2) after DA treatment.
The control was a non-DA-treated culture.
Statistics
All data were presented in terms of mean 6 SD and P
value less than 0.05 was considered significant. While
comparison of two groups was made by paired t-test,
comparison within groups was made by ANOVA.
RESULTS
Expression of DA receptor genes in MC3T3-E1 cells
Nested polymerase chain reaction (Nested PCR; primers in
Table 1), showed clear nested PCR bands of all five DA
receptors without any nonspecific bands (Figure 1). The
size of PCR products from both mouse brain and MC3T3-
E1 cells were found to be identical.18
Western blot analysis of DA receptors in MC3T3-E1 cells
The band size of DA receptors of mouse brain and the
MC3T3-E1 cells was almost identical, and the band specifi-
city against antibodies was also high in both groups
(Figure 2). Antibodies against D1, D2, D3, D4, and D5
receptor proteins recognized band size around 70, 50,
40, 70, and 50 kD respectively in both mouse brain and
MC3T3-E cells. Although all five DA receptor expressions
were clearly detected on day 0, day 4, day 7, and day
14, there is not much changes in the level of expression
over time.
Optimization of DA treatment
DA concentration was optimized not only to prevent cell
death due to overdose but also for a stimulatory effect on
MC3T3-E1 cells. This was accomplished by investigating
the effect of various DA concentrations as well as length
of DA treatment. As illustrated in Figure 3, the highest OD
values for the cells that were exposed at each time and
dose are 0.32 6 0.04 in 24 hours at the concentration of 100
mmol?L21, 0.46 6 0.02 in 36 hours with 50 mmol?L21, 0.51 6
0.02 in 48 hours with 50 mmol?L21, and 0.66 6 0.02 with 0
mmol?L21 in 72 hours (data not shown here). Collectively,
the highest OD value (0.51 6 0.02) was acquired for the
cells treated with 50 mmol?L21 of DA for 48 hours, which is
considered as the most effective condition for studies less
than 72 hours. After the treatment of cells with 100 and 200
mmol?L21 of DA for 36 and 48 hours, we could observe color
darkening in culture media. Most of the cells that were
treated with higher than 100 mmol?L21 of DA died. Thus,
the 50 mmol?L21 of DA was used for experiments on cell
proliferation up to 7 days of culture described below.
Effect of DA on MC3T3-E1 cell proliferation
Based on the DA optimization data, MC3T3-E1 cells were
supplied with fresh media (10% FBS) containing 50 mmol?L21
DA every 48 hours for 7 days. A significant difference in
growth was observed up to day 4 between the DA-treated
and non-treated cells (Figure 4a). The cell number in both
groups increased insignificantly at almost the same rate
Table 2. Primers for real-time PCR for osteogenic gene expression
Target Primer Sequence (59–39) Size (bp)
ALP F: AACCCAGACACAAGCATTCC 200
R: GCCTTTGAGGTTTITGGTCA
BSP F: CCGGCCACGCTACTTICTI 66
R: TGGACTGGAAACCGTITCAGA
OC F: CTGACCTCACAGATGCCAA 185
R: GGTCTGATAGTCTGTCACAA
OP F: TGCCTGACCCATCTCAGAA 107
R: ATTCATCCGAGTCCACAGAA
OSX F: CCTCTCGACCCGACTGCAGATC 107
R: AGCTGCAAGCTCTCTGTAACCATGAC
RUNX2 F: GAATGGCAGCACGCTATIAAATCC 103
R: GCCGCTAGAATICAAAACAGTIGG
Col1a2 F: GGCTCTAGAGGTGAACGTGG 139
R: CACCAGGGGCACCATTAACT
GAPDH F: TGAGGTGACCGCATCTICTIG 101
R: TGGTAACCAGGCGTCCGATA
ALP, alkaline phosphatase; BSP, bone sailoprotein; OC, osteocalcin; OSX, ostrix,
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Figure 1. Expression of dopamine (DA) receptor genes in cultured
MC3T3-E1 cells. Total RNAs extracted from MC3T3-E1 cells were ana-
lyzed by RT-PCR using specific primers for each DA receptor (Table 1).
The size of the PCR products was analyzed by electrophoresis compared
with mRNAs extracted from mouse brain (Br) tissue. D1, D2, D3, D4, and
D5 receptors were consistently expressed in both MC3T3-E1 cells and Br
tissue. bp, base pair.
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up to day 7. DA treatment provided higher growth in the
treated group than in the non-treated group only from
day 1 to day 4. The value of OD measurement in the
DA-treated group (0.76 6 0.05) on day 3 was significantly
higher than that of the non-treated group (0.65 6 0.02,
P , 0.05). However, MC3T3-E1 cells in both DA-treated
and non-treated media represented almost the same
growth rate from day 4 to day 7 without significant differ-
ence in the proliferation rate (P . 0.05). Beginning with cell
density of 50 000 the confluent after 7 days of culture
reached the plateau of the growth curve in both groups.
Compared with the control cells lacking DA treatment, the
MC3T3-E1 cells displayed that the enhanced proliferation
by the DA (50mmol?L21) treatment up to 7 days. In addition,
BrdU assay indicated higher number of BrdU1 cells in DA-
treated group on day 1 but will have similar number of
BrdU1 cells on days 3, 5, and 7 (Figure 4c).
MC3T3-E1 cells were supplied with media (3% FBS) con-
taining 50 mmol?L21 DA every 48 hours for 7 days. Significant
differences in DA-treated cells on both days 3 and 5 were
observed compared to non-treated cells. Although the
overall cell growth in 3% serum was slower than in 10%
serum, DA treatment on the cells clearly showed more
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Figure 2. Western blot analysis of DA receptor expression on the MC3T3-E1 osteoblasts during osteogenic differentiation on days 0, 4, 7, and 14. Br was
used as control to identify the correct size of each DA receptor protein and binding specificity against each DA receptor antibody. Each loading was
normalized by beta actin and quantified using Image J software. The relative molecular mass of significant band identified on the blots was labelled on


























Figure 3. Optimization of DA concentration and treatment duration on
MC3T3-E1 cells using MTS assay. Total of 50 000 cells per 35 mm dish were
seeded overnight and exposed to various concentrations (0, 50, 100, and
200mmol?L21) of dopamine for 24, 36, and 48 hours of culture respectively.
Cell proliferation was most effective with 50 mmol?L21 of DA treatment
after 48 hours (n 5 3 measurements from each three independent
samples per group, *P , 0.05 vs. 0 mmol?L21 dopamine group).
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Effect of DA on mineralization
Bone mineralization resulting from calcium deposition is
known as a late marker in osteogenic differentiation.
Most mineralization was initiated after 7 days, the results
on days 10, 14, 18, and 21 (Figure 5). From the scanned
image of mineralization (Figure 5a), the DA-treated
group (50 mmol?L21) showed higher levels of mineraliza-
tion as shown by a darker color, rougher particles and
widely branched deposits in comparison with that in the
non-treated group. The difference in mineralization was
most significant after 18 days between the two groups.
After 21 days, difference in mineralization could not be
assessed due to over-deposition of minerals. The nega-
tive control group without DA showed no mineral depos-
its even after 21 days. The mineralization was induced
using DA treated on the cells under non-osteogenic
media. Although no distinct mineral deposits were
observed until 14 days, only small, weakly stained mineral
particles were observed 21 days, which was different
than the mineral deposits in the other two groups under
osteogenic media. The shape of the mineral nodules
after DA treatment indicated the larger average size of
nodules (.1 mm in diameter) and more branched with
neighboring nodules than those in the group without DA
treatment.
Both CPC (Figure 5b) and Image J analysis (Figure 5c)
extraction indicated an increased area of calcium nodules
in the DA-treated group compared with the non-treated
group on days 10, 14, 18, and 21. Mineralization was signifi-
cantly higher at the 10th, 14th, and 18th days for the
DA-treated group, compared to the non-treated group.
However, the level of mineralization was just little higher
on the 21st day of differentiation with DA.
Effect of DA on osteogenic gene expression with
receptor antagonists
To compare the osteogenic gene expression, the MC3T3-
E1 cell culture was categorized as (i) cells cultured in
growth media with or without DA, (ii) the cells cultured in
osteogenic media with or without DA, and (iii) the cells
blocked by antagonists and then cultured in both growth
and osteogenic media with DA. Any elevated mRNA
expression of osteogenic genes was considered to have
higher osteogenic potential by the cells.
To confirm that DA treatment enhanced mineralization,
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Figure 4. Effect of DA on cell proliferation. MTS proliferation assays were performed on days 1, 3, 5, and 7 in growth media containing 10% FBS (a) and
3% FBS (b), respectively. Proliferating cells were detected by BrdU assay (c), scale: 100 mm. Cells were treated with 50 mmol?L21 DA on day 0. The
medium was changed every 48 hours with freshly prepared DA solution. The assay was performed in 96-well plates with n 5 3 measurements from
each three independent samples per group.
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whether osteogenic gene expression is also increased in
MC3T3-E1 cells. Our data showed that the expression of
the osteogenic genes is different in cells with DA treatment
than those without DA in osteogenic and growth media at
either day 4 or day 7 (Figure 6).
Osteogenic media-stimulated osteogenic gene
expression was higher than the osteogenic gene express-
ion in growth media on both day 4 and day 7 (P , 0.05).
However, the osteogenic gene expression in osteogenic
media showed significant decrease on both day 4 and
day 7 after DA treatment. Particularly, Runx2 gene was
suppressed after blocking with combined antagonists for
DA receptors, SCH233390 and GR103691, while the rest of
the genes were elevated level of induction regardless of
the antagonists treatment on day 4. But all the osteogenic
genes in osteogenic media were decreased after
antagonists treatment on day 7 except no obvious differ-
ence on OSX gene (Figure 6a).
DA alone induced osteogenic gene expression level. The
level of each gene expression of MC3T3-E1 cells in growth
media increased with DA treatment on either day 4 or day 7
except the collagen 1 gene expression on day 7, which did
not show much effect on its gene expression even after DA
treatment. The gene expression by DA treatment after
antagonists treatment was significantly inhibited by the sti-
mulatory effect of the DA except the collagen gene at
7 days. In contrast, the DA treatment on the cells cultured
in the osteogenic media significantly reduced all the
gene expression at both day 4 and day 7 (Figure 6b).
DISCUSSION
Although the expression of serotonin and gamma-
aminobutyric acid (GABA) receptors in osteoblasts was
previously reported,17–18 the presence of DA receptors in
osteoblasts has not been discussed. In this study, we found
that DA receptors are expressed in MC3T3-E1 cells and are
functional to induced mineralization. To our knowledge,
this study is the first to report that osteoblasts express DA
receptors and the cellular effect of DA treatment. DA












































































Figure 5. Mineral nodule formation after Alizarin Red S staining and quantification. (a) DA treatment enhanced mineralization by MC3T3-E1 cells
cultured with osteogenic media. The level of mineralization was equalized in both DA-treated (50 mmol?L21) and non-treated group after 21 days. DA
effect was also observed in the cells cultured with growth media for 21 days forming small minerals. Scale bar represents 200 mm. (b) Semi-quantitative
analysis of Alizarin Red S-stained particles by CPC extraction method. Extracted solution was measured by the absorbance at 570 nm (n 5 6, *P , 0.05
vs. in osteogenic media without DA, and {P , 0.05 vs. in growth media without DA). (c) Image J analysis of the mineral coverage of the culture dish.
Both CPC and Image J analysis yielded similar results.
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patterns not only in the central nervous system (CNS) such
as brain and spinal cord but also in the peripheral nervous
system (PNS).19–20 The roles and functions of DA and DA
receptors in osteoblasts are unknown. In addition, there is
no report of osteoblast releasing DA to date. We per-
formed western blotting for tyrosine hydroxylase (TH)
expression, which is responsible for catalyzing the conver-
sion of the amino acid L-tyrosine to L-3,4-dihydroxypheny-
lalanine (L-DOPA) for cells that release DA. However, we
did not detect any TH expression in osteoblasts even
though it was detected in brain lysates used as a positive
control (data not shown). The source of DA is likely extra-
celluar and not from osteoblasts themselves.
In this study, RT-PCR and western blot analysis were
assessed to examine DA receptor mRNA and protein
expression in MC3T3-E1 cells. Surprisingly, all five DA recep-
tors genes and proteins were expressed as identified by
the RT-PCR and western blot, respectively.
Although we did not measure direct affinity between DA
and DA receptors, DA receptors (D1–D5) are known to be
activated by DA with various affinities ranging from the
nanomolar to micromolar range. Different subtypes of DA
receptors vary significantly in their sensitivity to DA agonists
and antagonists. The dissociation constants (Ki values) of
the DA agonists were determined with selective radioli-

































































































Figure 6. The osteogenic gene expression of MC3T3-E1 cells that were cultured with/without DA (50 mmol?L21), as evaluated with real-time
PCR analysis to detect ALP, BSP, OC, OSX, RUNX2, and Collagen1a2 genes. Each gene data was presented as fold changes in the control,
dopamine treated, and dopamine treated with antagonists (SCH233390 and GR103691) in growth media (a) and osteogenic media (b). The real-
time PCR data were normalized with GAPDH expression (n 5 3 per group; *P , 0.05 compared with control and antagonists treated group at
same time point).
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Institute of Mental Health Psychoactive Drug Screening
Program database (http://pdsp.med.unc.edu), the Ki
values for the five DA receptors were 130 nmol?L21 for D1,
598 nmol?L21 for D2, 32.5 nmol?L21 for D3, 182.6 nmol?L21 for
D4, and 228 nmol?L21 for D5.
Plasma concentration of DA in healthy human popu-
lation is reported to be 21.8 6 9.5 ng?L21.21 Also, Mayo
Clinic Lab reference value shows normal plasma concen-
tration of DA should be less than 30 pg?mL21 (50.196
nmol?L21). Although physiological DA concentration is
much lower than what we used to stimulate MC3T3-E1
cells, there is no previous report on DA concentration in
bone or DA effects on osteoblastic cells. Our study shows
there was no clear cellular toxicity from DA concentration
with 50 mmol?L21 on osteoblasts. Although we stimulate
with a higher concentration of DA than the physiological
condition to osteoblasts, our study is limited on in vitro cul-
ture condition, not in vivo physiological conditions. If the
cells stimulated by high concentration of DA can improve
osteogenic differentiation in vitro without toxic effect, we
can consider them as good candidate for bone regen-
eration in tissue engineering.
There is strong evidence in neuronal cells that DA can
cause cytotoxic effects by both oxidative stress of reactive
oxygen species (free radicals) and formation of hydrogen
peroxide.22 Previously Clement et al. proved that DA-
induced cell death is not specific only for neuronal cells
but also for the rat pheochromocytoma cell line (PC12)
and the M14 human melanoma cell line.23 Future dopa-
minergic toxicity test and apoptosis studies for MC3T3-E1
are warranted. One of the most reliable methods to
detect the apoptotic cells affected by the DA is caspase
activity assay, which detects a relatively early event in
apoptosis. The detection method for caspase is reliable
and does not require a washing step. Although the
TUNEL assay is known as the gold standard to detect apop-
tosis, TUNEL detects necrotic cells as well. Moreover, it is a
late event in apoptosis so there is a high chance to wash
out dead cells during the staining procedures, which may
result in inaccurate quantitation. It’s also a good way to
apply DA antagonists to observe whether it can prevent
MC3T3-E1 cell death at high dosage and this will show the
apoptotic effect is from DA not from something else.
We further characterized the effect of DA on osteogenic
activities by assessing proliferation, osteogenic differenti-
ation and formation of mineralized bone-like nodules.
While seeding with low number of cells (,20 000) can
cause both inaccurate and inconsistent cell seeding,
these cells divide rapidly and become confluent in only
a few days. Thus, the initial cell number was optimized as
50 000 cells to allow the cells to be cultured for 7 days to
avoid contact inhibition. Using a low serum medium
for proliferation, we clarified the role that DA plays in
promoting proliferation during 7 days of culture. Since
FBS activates cellular mitogenic activity, it is important to
test proliferation in low serum (3%) condition to observe
better effect by DA, not by serum. Controls (no DA) were
used and compared the proliferation taking into account
the background response due to the presence of serum
proteins in the culture medium. Proliferating cells were
observed using BrdU assay. About 30% of cells were BrdU
positive in each group except in the DA-treated group on
day 1. BrdU positive cell number was higher than that in
untreated group. Initially, DA could have an effect on the
cell attachment.
While the nodules formed with DA treatment were larger
and more branched, and connected with neighboring
particles, the group without DA treatment showed smaller
nodules that were not connected. Sometimes, discrep-
ancies among the degree of mineral deposition may be
due to differences in the differentiation stage, cell passage
and condition culture period before differentiation trig-
gered and the time that cells are grown in osteogenic
media. Therefore, we also used growth media, in addition
to osteogenic media to confirm the effect of DA on osteo-
blasts. Future studies can clarify the molecular mechanism
of how DA stimulates mineralization through DA receptors.
In contrast to other research studies that focused on the
effect of cells on the coated substrates, this study provided
clearer insight of the effect of DA on bone cells by adding a
known concentration of DA directly to the culture media.
Real-time PCR was performed to quantify the expression
of osteoblast-related genes (Table 2) in MC3T3-E1 cells
after DA treatment in both growth and osteogenic media.
Interestingly, all the genes investigated were significantly
upregulated by culturing in growth media for either day 4
or day 7. To investigate whether DA affects osteogenic
differentiation is specific via DA receptors, we used DA
receptor antagonists SCH233390 (D1 and D5 blocker)
and GR103691 (D3 blocker) to block DA receptors. The
results demonstrated that gene expression, which was sti-
mulated by DA treatment (50 mmol?L21), was completely
blocked by administration of the antagonists. However, all
the gene expression of MC3T3-E1 cells cultured in osteo-
genic media decreased after DA treatment possibly due
to a chemical reaction between the osteogenic media
and DA. The antagonists also did not block the effect of
the DA treatment.
Although gene expression in osteogenic media did not
show any DA effects, the mineralization under osteogenic
media was increased by DA. From these results, our
assumption is that DA can directly interact with either
b-glycerophosphate or ascorbic acid during osteogenic
differentiation to decrease gene expression and further
studies on the interaction should be investigated in future
experiments. At the same time, DA antagonists also did not
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have any effect on most of the osteogenic gene express-
ion in osteogenic media. One possible assumption is that
the binding of the DA antagonists to the DA receptors
might be inhibited by b-glycerophosphate or ascorbic
acid. The other possibility is the reaction of antagonists
with b-glycerophosphate or ascorbic acid changes their
chemical conformation and prevents binding to the
receptors. Further chemical analysis will be required
before the osteogenic gene expression study by DA is
attempted in osteogenic media. One limitation of our
study is the use of multiple inhibitors at one time, which
does not delineate the role of individual DA receptor. It is
important to investigate the role of each DA receptor ant-
agonist for confirmation of each DA receptor-mediated
biological effects in the future.
In this study, DA receptors were expressed in MC3T3-E1
osteoblasts cells and are functional. Direct administration
of DA-promoted cellular proliferation and mineralization
and was confirmed by using specific DA receptor antago-
nists. Our findings suggest that DA can enhance bone
regeneration, possibly in association with novel bone scaf-
fold, HGCS-PDA scaffold in bone tissue engineering. Duel
effect of DA on both osteoblasts and HGCS-PDA scaffold
may lead to a novel strategy of bone regeneration for
future orthopedic application.
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